%A Yan Jing, Liu Juan, Zhou Xia, Zhu Lijing, Yang Mi, Kong Weiwei, Ren Wei, Yang Yang, Qian Xiaoping, Liu Baorui %T Appliation of simultaneous integrated boostintensity modulated radiotherapy for metastatic malignancies palliative care %0 Journal Article %D 2016 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2016.06.008 %P 433-435 %V 43 %N 6 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9975.shtml} %8 2016-06-08 %X ObjectiveTo study the effect and feasibility of simultaneous integrated boostintensity modulated radiotherapy (SIBIMRT) for metastatic malignancies palliative care patients with metastatic malignant cancer. MethodsFortyfive patients with metastatic malignant cancer were treated with SIBIMRT for 10 to 28 fractions. The gross target volume (GTV) was 2.05.0 Gy per fraction, and the marginal dose of the planning target volume (PTV) was 1.83.0 Gy per fraction. For comparing the different delivering techniques, the three dimensionalconformal radiotherapy (3DCRT) plan for each patient was optimized. The effects and adverse effects were evaluated in the first month′s followup and every three months thereafter. ResultsAll patients completed the radiation therapy except for one who developed severe hepatic abscess. Nineteen patients received concurrent intravenous or oral chemotherapy or targeted drug therapies. The proportion of patients without adverse reaction was 38.64%(17/44), and the incidence rate of grade ⅠⅡ digestive tract or bone marrow suppression was 56.82% (25/44). Only 3 patients (6.82%) occurred grade Ⅲ bone marrow suppression, and no grade Ⅲ gastrointestinal reaction and Ⅳ adverse reaction occurred. The mean doses of GTV were (5 556.1±925.6) cGy for SIBIMRT and (4 491.5±881.4) cGy for 3DCRT, with 23.7% increase (t=15.492, P=0.00). One hundred and sixtyseven organs at risk (OARs) including lungs, intestine, spine, kidneys and liver were evaluated. Seventytwo OARs had decreased irradiation dose with SIBIMRT compared with 3DCRT, the range of the decrease ratio was 0.50%77.43%, with a mean value of 19.71%. Ninetyfive OARs had elevated irradiation dose with SIBIMRT compared with 3DCRT, the range of the increase ratio was 0.59%86.71%, with a mean value of 18.13%. The total mean value was increased 0.86%. So the SIBIMRT was acceptable. The median followup duration was 10 months (526 months). Two patients dropped out. The relapsefree rate within the radiation field was 95.23% (40/42). ConclusionSIBIMRT can significantly increase radiation doses of the tumor fields. The doses of OARs with SIBIMRT are increased or some decreased, and the range of the increased dose is indistinctive, and the patients are well tolerated.